Use of Statins and Outcomes in Intracerebral Hemorrhage Patients

Fazeel M. Siddiqui, Carl D. Langefeld, Charles J. Moomaw, Mary E. Comeau, Padmini Sekar, Jonathan Rosand, Stella Kidwell, Sharyl Martini, Jennifer L. Osborne, Sonja Stutzman, Christiana Hall, Daniel Woo

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background and Purpose-Statin use may be associated with improved outcome in intracerebral hemorrhage patients. However, the topic remains controversial. Our analysis examined the effect of prior, continued, or new statin use on intracerebral hemorrhage outcomes using the ERICH (Ethnic/Racial Variations of Intracerebral Hemorrhage) data set. Methods-We analyzed ERICH (a multicenter study designed to examine ethnic variations in the risk, presentation, and outcomes of intracerebral hemorrhage) to explore the association of statin use and hematoma growth, mortality, and 3-month disability. We computed subset analyses with respect to 3 statin categories (prior, continued, or new use). Results-Two thousand four hundred and fifty-seven enrolled cases (mean age, 62 years; 42% females) had complete data on mortality and 3-month disability (modified Rankin Scale). Among those, 1093 cases were on statins (prior, n=268; continued, n=423; new, n=402). Overall, statin use was associated with reduced mortality and disability without any effect on hematoma growth. This association was primarily driven by continued/new statin use. A multivariate analysis adjusted for age and major predictors for poor outcome showed that continued/new statins users had good outcomes compared with prior users. However, statins may have been continued/started more frequently among less severe patients. When a propensity score was developed based on factors that could influence a physician's decision in prescribing statins and used as a covariate, continued/new statin use was no longer a significant predictor of good outcome. Conclusions-Although statin use, especially continued/new use, was associated with improved intracerebral hemorrhage outcomes, this effect may merely reflect the physician's view of a patient's prognosis rather than a predictor of survival.

Original languageEnglish (US)
Pages (from-to)2098-2104
Number of pages7
JournalStroke
Volume48
Issue number8
DOIs
StatePublished - Aug 1 2017

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Cerebral Hemorrhage
Hematoma
Mortality
Physicians
Propensity Score
Growth
Multicenter Studies
Multivariate Analysis

Keywords

  • hematoma
  • hydroxymethylglutaryl-CoA reductase inhibitors
  • Intracerebral hemorrhage
  • mortality
  • outcome

ASJC Scopus subject areas

  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine
  • Advanced and Specialized Nursing

Cite this

Siddiqui, F. M., Langefeld, C. D., Moomaw, C. J., Comeau, M. E., Sekar, P., Rosand, J., ... Woo, D. (2017). Use of Statins and Outcomes in Intracerebral Hemorrhage Patients. Stroke, 48(8), 2098-2104. https://doi.org/10.1161/STROKEAHA.117.017358

Use of Statins and Outcomes in Intracerebral Hemorrhage Patients. / Siddiqui, Fazeel M.; Langefeld, Carl D.; Moomaw, Charles J.; Comeau, Mary E.; Sekar, Padmini; Rosand, Jonathan; Kidwell, Stella; Martini, Sharyl; Osborne, Jennifer L.; Stutzman, Sonja; Hall, Christiana; Woo, Daniel.

In: Stroke, Vol. 48, No. 8, 01.08.2017, p. 2098-2104.

Research output: Contribution to journalArticle

Siddiqui, FM, Langefeld, CD, Moomaw, CJ, Comeau, ME, Sekar, P, Rosand, J, Kidwell, S, Martini, S, Osborne, JL, Stutzman, S, Hall, C & Woo, D 2017, 'Use of Statins and Outcomes in Intracerebral Hemorrhage Patients', Stroke, vol. 48, no. 8, pp. 2098-2104. https://doi.org/10.1161/STROKEAHA.117.017358
Siddiqui FM, Langefeld CD, Moomaw CJ, Comeau ME, Sekar P, Rosand J et al. Use of Statins and Outcomes in Intracerebral Hemorrhage Patients. Stroke. 2017 Aug 1;48(8):2098-2104. https://doi.org/10.1161/STROKEAHA.117.017358
Siddiqui, Fazeel M. ; Langefeld, Carl D. ; Moomaw, Charles J. ; Comeau, Mary E. ; Sekar, Padmini ; Rosand, Jonathan ; Kidwell, Stella ; Martini, Sharyl ; Osborne, Jennifer L. ; Stutzman, Sonja ; Hall, Christiana ; Woo, Daniel. / Use of Statins and Outcomes in Intracerebral Hemorrhage Patients. In: Stroke. 2017 ; Vol. 48, No. 8. pp. 2098-2104.
@article{6d5cc110f80d4c0eb0cc17155364400b,
title = "Use of Statins and Outcomes in Intracerebral Hemorrhage Patients",
abstract = "Background and Purpose-Statin use may be associated with improved outcome in intracerebral hemorrhage patients. However, the topic remains controversial. Our analysis examined the effect of prior, continued, or new statin use on intracerebral hemorrhage outcomes using the ERICH (Ethnic/Racial Variations of Intracerebral Hemorrhage) data set. Methods-We analyzed ERICH (a multicenter study designed to examine ethnic variations in the risk, presentation, and outcomes of intracerebral hemorrhage) to explore the association of statin use and hematoma growth, mortality, and 3-month disability. We computed subset analyses with respect to 3 statin categories (prior, continued, or new use). Results-Two thousand four hundred and fifty-seven enrolled cases (mean age, 62 years; 42{\%} females) had complete data on mortality and 3-month disability (modified Rankin Scale). Among those, 1093 cases were on statins (prior, n=268; continued, n=423; new, n=402). Overall, statin use was associated with reduced mortality and disability without any effect on hematoma growth. This association was primarily driven by continued/new statin use. A multivariate analysis adjusted for age and major predictors for poor outcome showed that continued/new statins users had good outcomes compared with prior users. However, statins may have been continued/started more frequently among less severe patients. When a propensity score was developed based on factors that could influence a physician's decision in prescribing statins and used as a covariate, continued/new statin use was no longer a significant predictor of good outcome. Conclusions-Although statin use, especially continued/new use, was associated with improved intracerebral hemorrhage outcomes, this effect may merely reflect the physician's view of a patient's prognosis rather than a predictor of survival.",
keywords = "hematoma, hydroxymethylglutaryl-CoA reductase inhibitors, Intracerebral hemorrhage, mortality, outcome",
author = "Siddiqui, {Fazeel M.} and Langefeld, {Carl D.} and Moomaw, {Charles J.} and Comeau, {Mary E.} and Padmini Sekar and Jonathan Rosand and Stella Kidwell and Sharyl Martini and Osborne, {Jennifer L.} and Sonja Stutzman and Christiana Hall and Daniel Woo",
year = "2017",
month = "8",
day = "1",
doi = "10.1161/STROKEAHA.117.017358",
language = "English (US)",
volume = "48",
pages = "2098--2104",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Use of Statins and Outcomes in Intracerebral Hemorrhage Patients

AU - Siddiqui, Fazeel M.

AU - Langefeld, Carl D.

AU - Moomaw, Charles J.

AU - Comeau, Mary E.

AU - Sekar, Padmini

AU - Rosand, Jonathan

AU - Kidwell, Stella

AU - Martini, Sharyl

AU - Osborne, Jennifer L.

AU - Stutzman, Sonja

AU - Hall, Christiana

AU - Woo, Daniel

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Background and Purpose-Statin use may be associated with improved outcome in intracerebral hemorrhage patients. However, the topic remains controversial. Our analysis examined the effect of prior, continued, or new statin use on intracerebral hemorrhage outcomes using the ERICH (Ethnic/Racial Variations of Intracerebral Hemorrhage) data set. Methods-We analyzed ERICH (a multicenter study designed to examine ethnic variations in the risk, presentation, and outcomes of intracerebral hemorrhage) to explore the association of statin use and hematoma growth, mortality, and 3-month disability. We computed subset analyses with respect to 3 statin categories (prior, continued, or new use). Results-Two thousand four hundred and fifty-seven enrolled cases (mean age, 62 years; 42% females) had complete data on mortality and 3-month disability (modified Rankin Scale). Among those, 1093 cases were on statins (prior, n=268; continued, n=423; new, n=402). Overall, statin use was associated with reduced mortality and disability without any effect on hematoma growth. This association was primarily driven by continued/new statin use. A multivariate analysis adjusted for age and major predictors for poor outcome showed that continued/new statins users had good outcomes compared with prior users. However, statins may have been continued/started more frequently among less severe patients. When a propensity score was developed based on factors that could influence a physician's decision in prescribing statins and used as a covariate, continued/new statin use was no longer a significant predictor of good outcome. Conclusions-Although statin use, especially continued/new use, was associated with improved intracerebral hemorrhage outcomes, this effect may merely reflect the physician's view of a patient's prognosis rather than a predictor of survival.

AB - Background and Purpose-Statin use may be associated with improved outcome in intracerebral hemorrhage patients. However, the topic remains controversial. Our analysis examined the effect of prior, continued, or new statin use on intracerebral hemorrhage outcomes using the ERICH (Ethnic/Racial Variations of Intracerebral Hemorrhage) data set. Methods-We analyzed ERICH (a multicenter study designed to examine ethnic variations in the risk, presentation, and outcomes of intracerebral hemorrhage) to explore the association of statin use and hematoma growth, mortality, and 3-month disability. We computed subset analyses with respect to 3 statin categories (prior, continued, or new use). Results-Two thousand four hundred and fifty-seven enrolled cases (mean age, 62 years; 42% females) had complete data on mortality and 3-month disability (modified Rankin Scale). Among those, 1093 cases were on statins (prior, n=268; continued, n=423; new, n=402). Overall, statin use was associated with reduced mortality and disability without any effect on hematoma growth. This association was primarily driven by continued/new statin use. A multivariate analysis adjusted for age and major predictors for poor outcome showed that continued/new statins users had good outcomes compared with prior users. However, statins may have been continued/started more frequently among less severe patients. When a propensity score was developed based on factors that could influence a physician's decision in prescribing statins and used as a covariate, continued/new statin use was no longer a significant predictor of good outcome. Conclusions-Although statin use, especially continued/new use, was associated with improved intracerebral hemorrhage outcomes, this effect may merely reflect the physician's view of a patient's prognosis rather than a predictor of survival.

KW - hematoma

KW - hydroxymethylglutaryl-CoA reductase inhibitors

KW - Intracerebral hemorrhage

KW - mortality

KW - outcome

UR - http://www.scopus.com/inward/record.url?scp=85021683592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021683592&partnerID=8YFLogxK

U2 - 10.1161/STROKEAHA.117.017358

DO - 10.1161/STROKEAHA.117.017358

M3 - Article

C2 - 28663510

AN - SCOPUS:85021683592

VL - 48

SP - 2098

EP - 2104

JO - Stroke

JF - Stroke

SN - 0039-2499

IS - 8

ER -